ClinicalTrials.gg
RecruitingNCT07649265Updated Nov 5, 2026

A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

A Phase 1 interventional study of HBM7020 in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingFirst site in Australia+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Planned enrollment
122nd of 140
63 · median 469
Started
2026
with 8 others
Phase 1
21 of 154
12 open now
Primary completion
2028-11
later than 17 of 20 live
Registered
153rd of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 122nd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 17 of the 20 other live ones, and was the 153rd registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Sjögren's Disease

Keywords

  • Autoimmune disease
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria for Healthy Participants (Part 1)

  1. Participants who are of non- or are using acceptable .
  2. (BMI) and body weight within an acceptable range.
  3. Good general health based on medical history, physical examination, (ECG), and laboratory assessments.

Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)

  1. BMI and body weight within an acceptable range.
  2. Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.

Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)

  1. Confirmed disease with appropriate supporting autoantibody findings.
  2. Stable background therapy prior to dosing.
  3. Active moderate to severe disease consistent with protocol-defined disease activity criteria for:

    • Systemic lupus erythematosus (SLE)
    • Systemic sclerosis (SSc)
    • Rheumatoid arthritis (RA)
    • Sjögren's disease (SjD)

Key Inclusion Criteria for Rescreening Participants (Part 2)

  1. Meets Part 2 disease-agnostic inclusion criteria.
  2. Stable background autoimmune therapy prior to dosing.
  3. Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.

Key Exclusion Criteria for Parts 1 and 2

  1. Pregnant or breastfeeding participants.
  2. Recent vaccination within protocol-defined timelines.
  3. medical history or abnormal physical examination findings.
  4. Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
  5. Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
  6. Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Part 1 and Part 2a Dose Escalation

    Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively.

    Drug: HBM7020

  • Experimental
    Part 2b

    Eligible patients may receive optional retreatment of HBM7020 in Part 2b

    Drug: HBM7020

Interventions

  • DrugHBM7020

    Liquid formulation, administered through intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48

    Time frame: Up to Week 48

  2. Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection

    Time frame: Up to Week 24

  3. Number of Participants With Dose limiting AE Evaluation During Dose Escalation

    Time frame: Up to Day 15

  4. Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Up to Week 24

  5. Number of Participants With Clinically Significant Changes in Physical Examination Findings

    Time frame: Up to Week 24

  6. Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Up to Week 20

  7. Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)

    Time frame: Up to Week 20

  8. Change From Baseline in Serum Ferritin

    Time frame: Up to Week 20

  9. Change From Baseline in Serum Immunoglobulin G (IgG)

    Time frame: Up to Week 20

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020

    Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)

  2. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020

    Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)

  3. Maximum Observed Plasma Concentration (Cmax) of HBM7020

    Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)

  4. Time to Maximum Observed Plasma Concentration (tmax) of HBM7020

    Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)

  5. Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020

    Time frame: Up to Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2028, 25 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 25 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 16, 2026
StartActual
Sep 24, 2026
Primary completionEst.
Nov 20, 2028
CompletionEst.
Nov 20, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added — first site in Australia
Show site
  • Q-Pharm Pty Ltd · Brisbane, Australia
Oct 13, 2026
Start date
Sep 15, 2026→Sep 24, 2026 (actual)
Oct 13, 2026
Eligibility
3 criteria edited
What changed in the criteria
  • EditedKey Disease-Agnostic Inclusion Criteria for Patient Participants (Part 12)
  • EditedKey Disease-Specific Inclusion Criteria for Patient Participants (Part 12)
  • EditedMeets Part 12 disease-agnostic inclusion criteria.
Nov 5, 2026
Interventions
Arms added: Part 1 and Part 2a Dose Escalation·Part 2b; arms removed: Part 1·Part 2
Nov 5, 2026
Primary outcomes
3 removed
What changed in the outcomes
  • RemovedChange From Baseline in Serum Interleukin-6 (IL-6)Time frame: Up to Week 20
  • RemovedChange From Baseline in Serum Tumour Necrosis Factor-Alpha (TNF-α)Time frame: Up to Week 20
  • RemovedChange From Baseline in Serum Interferon-Gamma (IFN-γ)Time frame: Up to Week 20
Nov 5, 2026
Title
A Trial in Healthy Adult Participants and Adults With Autoimmune DiseaseDiseases to Test How HBM7020 is Tolerated and AbsorbedHow it Behaves in the Body
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Eligibility 3 criteria edited
    What changed in the criteria
    • EditedKey Disease-Agnostic Inclusion Criteria for Patient Participants (Part 12)
    • EditedKey Disease-Specific Inclusion Criteria for Patient Participants (Part 12)
    • EditedMeets Part 12 disease-agnostic inclusion criteria.
    Primary outcomes 3 removed
    What changed in the outcomes
    • RemovedChange From Baseline in Serum Interleukin-6 (IL-6)Time frame: Up to Week 20
    • RemovedChange From Baseline in Serum Tumour Necrosis Factor-Alpha (TNF-α)Time frame: Up to Week 20
    • RemovedChange From Baseline in Serum Interferon-Gamma (IFN-γ)Time frame: Up to Week 20
    Interventions Arms added: Part 1 and Part 2a Dose Escalation·Part 2b; arms removed: Part 1·Part 2
    Title A Trial in Healthy Adult Participants and Adults With Autoimmune DiseaseDiseases to Test How HBM7020 is Tolerated and AbsorbedHow it Behaves in the Body
    + 1 other change: verification date
  2. Oct 13, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Australia
    Show site
    • Q-Pharm Pty Ltd · Brisbane, Australia
    Start date Sep 15, 2026→Sep 24, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07649265
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Sep 24, 2026
Primary completion
Nov 20, 2028 (estimated)
Completion
Nov 20, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Otsuka Call Center
Contact
otsukaprofessionalservices@otsuka-us.com
844-687-3522

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion